Meyer L.a· Bohlscheid A.b· Lemmer O.c· van de Plas J.c· Leboutte F.c· Hadaschik B.A.d· Neisius A.c· Willinek W.A.b

Author affiliations

aUniversity of Bonn, Bonn, Germany
bDepartment of Radiology, Neuroradiology, Sonography and Nuclear Medicine, Hospital of the Barmherzige Brüder Trier, Trier, Germany
cDepartment of Urology and Pediatric Urology, Hospital of the Barmherzige Brüder Trier, Trier, Germany
dDepartment of Urology, University Hospital Essen, Essen, Germany

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: December 07, 2022
Accepted: February 20, 2023
Published online: April 18, 2023

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 4

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Introduction: Diffusion-weighted imaging (DWI) as part of multiparametric magnetic resonance imaging (mpMRI) is an important sequence for the detection of prostate cancer (PCa). The objective of this retrospective analysis was to evaluate changes in apparent diffusion coefficient (ADC) measurements in biopsy-proven PCa undergoing TULSA-PRO (MR-guided transurethral ultrasound ablation of the prostate) at 3.0 T after 1, 3, and 6–12 months posttreatment. Methods: Nineteen patients underwent follow-up examinations after 1, 3, and 6–12 months including mpMRI at 3.0 T and urological-clinical examinations with quantitative analysis of ADCs. Results: In PCa, a significant increase of ADC values after 6–12 months was measured after TULSA-PRO treatment by 29.1% (pre-TULSA: 0.79 ± 0.16 × 10−3 mm2/s, 6–12 months: 1.02 ± 0.35 × 10−3 mm2/s), while the corresponding value in the reference tissue decreased by 48.5% (pre-TULSA: 1.20 ± 0.15 × 10−3 mm2/s, 6–12 months: 0.91 ± 0.29 × 10−3 mm2/s). The mean ADC values in the early follow-up groups at 1 and 3 months did not change significantly. Conclusion: DWI with ADC as part of mpMRI can serve as a biomarker to dynamically monitor the follow-up after TULSA after 6–12 months. For early posttreatment progression, it is not suitable due to too many confounding variables.

© 2023 S. Karger AG, Basel

References Koch-Institut R. Krebs in Deutschland für 2015/2016. 12. Ausgabe: Robert Koch Inst; 2019. p. 160. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020 Jan;77(1):38–52. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008 Feb;15(1):3866–71. Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and established technology in focal ablation of the prostate: a systematic review. Eur Urol. 2017 Jan;71(1):17–34. Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate cancer. J Urol. 2021 Mar;205(3):769–79. Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, et al. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. Eur Radiol. 2019 Jan;29(1):299–308. Lumiani A, Samun D, Sroka R, Muschter R. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). Urol Oncol. 2021;39(12):830.e9–e16. Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, et al. Magnetic resonance imaging–guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: a prospective phase 1 clinical trial. Eur Urol. 2016;70(3):447–55. Mueller-Wolf M, Röthke M, Hadaschik B, Pahernik S, Chin J, Relle J, et al. Transurethral MR-thermometry guided ultrasound ablation of the prostate: the heidelberg experience during phase I of the TULSA-PRO device trial. Magnetom Flash. 2016;66(3). Esen T, Turkbey B, Patel A, Futterer J. Multiparametric MRI in prostate cancer. Biomed Res Int. 2014;2014:296810. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol. 2009 Jun;192(6):1471–80. Tamada T, Ueda Y, Ueno Y, Kojima Y, Kido A, Yamamoto A. Diffusion-weighted imaging in prostate cancer. New York, MAGMA; 2021 Sep. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF2nd. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol. 2010 Apr;194(4):W316–22. Baliyan V, Das CJ, Sharma S, Gupta AK. Diffusion-weighted imaging in urinary tract lesions. Clin Radiol. 2014 Aug;69(8):773–82. Mäkelä P, Anttinen M, Suomi V, Steiner A, Saunavaara J, Sainio T, et al. Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. Acta Radiol. 2020 Nov;62(12):1687–95. Burtnyk M, Chopra R, Bronskill M. Simulation study on the heating of the surrounding anatomy during transurethral ultrasound prostate therapy: a 3D theoretical analysis of patient safety. Med Phys. 2010 Jun;37(6):2862–75. Chopra R, Colquhoun A, Burtnyk M, N’djin WA, Kobelevskiy I, Boyes A, et al. MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology. 2012 Oct;265(1):303–13. Tay KJ, Amin MB, Ghai S, Jimenez RE, Kench JG, Klotz L, et al. Surveillance after prostate focal therapy. World J Urol. 2019 Mar;37(3):397–407. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging: reporting and data system: 2015, version 2. Eur Urol. 2016 Jan;69(1):16–40. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019 Sep;76(3):340–51. Beetz NL, Haas M, Baur A, Konietschke F, Roy A, Hamm CA, et al. Inter-reader variability using PI-rads v2 versus PI-rads v2.1: most new disagreement stems from scores 1 and 2. Rofo. 2022 Aug;194(8):852–61. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974 Jan;111(1):58–64. D’Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol. 2006 Dec;176(6 Pt 2):S11–5. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74. Silvera S, Oppenheim C, Touzé E, Ducreux D, Page P, Domigo V, et al. Spontaneous intracerebral hematoma on diffusion-weighted images: influence of T2-shine-through and T2-blackout effects. AJNR Am J Neuroradiol. 2005 Feb;26(2):236–41. Maffazzioli L, Zilio MB, Klamt AL, Duarte JA, Mazzini GS, Campos VJ, et al. ADC as a predictor of pathologic response to neoadjuvant therapy in esophageal cancer: a systematic review and meta-analysis. Eur Radiol. 2020 Jul;30(7):3934–42. Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007 Jan;25(1):1–13. Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol. 2008 May;190(5):1180–6. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009 Feb;11(2):102–25. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007 Sep;25(26):4104–9. Ghafoor S, Becker AS, Stocker D, Barth BK, Eberli D, Donati OF, et al. Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound. Abdom Radiol. 2020 Nov;45(11):3882–95. Lee JY, Chang IH, Moon YT, Kim KD, Myung SC, Kim TH, et al. Effect of prostate biopsy hemorrhage on MRDW and MRS imaging. Korean J Urol. 2011 Oct;52(10):674–80. Kirkham APS, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology. 2008;246(3):833–44. Rouvière O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol. 2001 Sep;40(3):265–74. Article / Publication Details

Received: December 07, 2022
Accepted: February 20, 2023
Published online: April 18, 2023

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 4

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.